Subscription-Based Pricing for Lenacapavir—Learning From Hepatitis C and Cabotegravir

JAMA 2026

View at publisher

Authors: Michael R. Rose, Charles W. Flexner, Victor Roy

DOI: 10.1001/jama.2025.24404

Cited by: 1

References: 6

Abstract

This Viewpoint discusses ways in which payer license agreements can facilitate widespread lenacapavir use, a key step in ending the HIV epidemic.

Hepatitis C virus research Pharmaceutical Economics and Policy HIV/AIDS drug development and treatment

References 6